Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 28:82:104508.
doi: 10.1016/j.amsu.2022.104508. eCollection 2022 Oct.

Tumour microenvironment: Modulating effects, challenges, and future perspectives of oncolytic virotherapy in Astrocytoma treatment

Wireko Andrew Awuah  1 , Helen Huang  2 , Jacob Kalmanovich  3 , Aashna Mehta  4 , Mrinmoy Kundu  5 , Abdul Rahman Toufik  1 , Resham Tanna  6 , Mohammad Mehedi Hasan  7 , Athanasios Alexiou  8 , Vladyslav Sikora  1
Affiliations

Tumour microenvironment: Modulating effects, challenges, and future perspectives of oncolytic virotherapy in Astrocytoma treatment

Wireko Andrew Awuah et al. Ann Med Surg (Lond). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

N/A.

Figures

Fig. 1
Fig. 1
The mechanism of action for Oncolytic Virotherapy (OVT) and the negative influence of the tumour microenvironment, blood-brain barrier, and heterogeneity on the efficacy of OVT. ECM, Extra-cellular matrix; PAMPs, Pathogen-associated molecular patterns; DAMPS, Damage-associated molecular patterns; DC, Dendritic cells; GBM, Glioblastoma multiforme; CAFs, Cancer-associated fibroblasts; CCN1, Cysteine-rich 61; BBB, Blood-brain barrier.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kapoor M., Gupta V., Astrocytoma . vol. 20. StatPearls Publishing; 2021. StatPearls. Treasure Island (FL) p. 2021. November.
    1. Zeng J., Li X., Sander M., Zhang H., Yan G., Lin Y. Oncolytic viro-immunotherapy: an emerging option in the treatment of gliomas. Front. Immunol. 2021;12 doi: 10.3389/fimmu.2021.721830Z. Published 2021 Oct 5. - DOI - PMC - PubMed
    1. Passaro C., Alayo Q., DeLaura I., et al. Correction: arming an oncolytic herpes simplex virus type 1 with a single-chain fragment variable antibody against PD-1 for experimental glioblastoma therapy. Clin. Cancer Res. 2020;26(3):758. doi: 10.1158/1078-0432.CCR-19-4091. - DOI - PubMed
    1. Patel D.M., Foreman P.M., Nabors L.B., Riley K.O., Gillespie G.Y., Markert J.M. Design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma. Hum. Gene. Ther. Clin. Dev. 2016;27(2):69–78. doi: 10.1089/humc.2016.031. - DOI - PMC - PubMed
    1. Liu Z., Zhao X., Mao H., Baxter P.A., Huang Y., Yu L., Wadhwa L., Su J.M., Adesina A., Perlaky L., et al. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma. Neuro Oncol. 2013;15:1173–1185. doi: 10.1093/neuonc/not065. - DOI - PMC - PubMed